Онкогематология (Nov 2022)

Eprex in the management of anemia related to lymphoproliferative disorders

  • P. N. Barlamov,
  • M. E. Golubeva,
  • G. V. Firsova,
  • E. R. Vasilyeva,
  • S. V. Meresiy,
  • O. V. Kanukova,
  • I. V. Klimova,
  • A. A. Shutilev,
  • M. A. Avtomenko,
  • V. V. Shekotov,
  • U. V. Zaychykina

DOI
https://doi.org/10.17650/1818-8346-2007-0-1-48-51
Journal volume & issue
Vol. 0, no. 1
pp. 48 – 51

Abstract

Read online

We report results of therapy with recombinant human erythropoietin alpha (Eprex) in patients (pts) with multiple myeloma and chronic lymphocytic leukaemia during chemotherapy. 14pts were included in this study. A level of endogenous erythropoietin, a serum iron binding capacity, and a level of serum iron were evaluated before the start of treatment. Oral iron medication prescribes in cases of established iron deficiency. A rate of increase of hemoglobin level was monitored on week 4, 8, and 12. Objective effect was achieved in 12 (85,7%) pts on 12-th week of treatment. Normal and moderately increased endogenous erythropoietin level was not a negative predicted factor for Eprex efficacy. We did not reveal complications of study drug. Therapy was executed in out-patient treatment regimen. We documented decrease of hospitalization necessity and transfusion dependence. An important treatment outcome resulted in improving of quality of life.

Keywords